27412759|t|Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis
27412759|a|Control of visceral leishmaniasis caused by Leishmania infantum and Leishmania donovani primarily relies on chemotherapy using an increasingly compromised repertoire of antileishmanial compounds. For evaluation of novel drugs, the Syrian golden hamster is considered as a clinically relevant laboratory model. In this study, two molecular parasite detection assays were developed targeting cathepsin-like cysteine protease B (CPB) DNA and 18S rRNA to achieve absolute amastigote quantification in the major target organs liver and spleen. Both quantitative PCR (qPCR) techniques showed excellent agreement with a strong correlation with the conventional microscopic reading of Giemsa-stained tissue smears. Using multiple single tissue pieces and all three detection methods, we confirmed homogeneity of infection in liver and spleen and the robustness of extrapolating whole organ burdens from a small single tissue piece. Comparison of pre - and post-treatment burdens in infected hamsters using the three detection methods consistently revealed a stronger parasite reduction in the spleen compared to the liver, indicating an organ - dependent clearance efficacy for miltefosine. In conclusion, this study in the hamster demonstrated high homogeneity of infection in liver and spleen and advocates the use of molecular detection methods for assessment of low (post-treatment) tissue burdens.
27412759	0	9	Molecular	T080	C1521991
27412759	10	19	detection	T061	C1511790
27412759	23	32	infection	T046	C3714514
27412759	33	44	homogeneity	T080	C1881065
27412759	49	55	impact	T080	C4049986
27412759	59	70	miltefosine	T109,T121	C0068006
27412759	71	80	treatment	T169	C1522326
27412759	86	107	Syrian golden hamster	T015	C0018561
27412759	117	136	Leishmania donovani	T204	C0023273
27412759	141	152	L. infantum	T204	C0023272
27412759	153	175	visceral leishmaniasis	T047	C0023290
27412759	176	183	Control	T169	C2587213
27412759	187	209	visceral leishmaniasis	T047	C0023290
27412759	220	239	Leishmania infantum	T204	C0023272
27412759	244	263	Leishmania donovani	T204	C0023273
27412759	284	296	chemotherapy	T061	C3665472
27412759	319	330	compromised	T033	C2945640
27412759	345	370	antileishmanial compounds	T121	C0304339
27412759	376	386	evaluation	T058	C0220825
27412759	390	395	novel	T080	C0205314
27412759	396	401	drugs	T121	C1254351
27412759	407	428	Syrian golden hamster	T015	C0018561
27412759	448	458	clinically	T080	C0205210
27412759	459	467	relevant	T080	C2347946
27412759	468	484	laboratory model	T170	C0086272
27412759	494	499	study	T062	C2603343
27412759	505	540	molecular parasite detection assays	T059	C1294355
27412759	556	565	targeting	T169	C1521840
27412759	566	600	cathepsin-like cysteine protease B	T116,T126	C0699919
27412759	602	605	CPB	T116,T126	C0699919
27412759	607	610	DNA	T114,T123	C0012854
27412759	619	623	rRNA	T114,T123	C0035701
27412759	635	643	absolute	T080	C0205344
27412759	644	654	amastigote	T204	C0686878
27412759	655	669	quantification	T081	C1709793
27412759	683	689	target	T169	C1521840
27412759	690	696	organs	T023	C0178784
27412759	697	702	liver	T023	C0023884
27412759	707	713	spleen	T023	C0037993
27412759	720	736	quantitative PCR	T063	C1709846
27412759	737	754	(qPCR) techniques	T063	C1709846
27412759	796	807	correlation	T080	C1707520
27412759	830	849	microscopic reading	T059	C0369671
27412759	853	867	Giemsa-stained	T059	C0523205
27412759	868	874	tissue	T024	C0040300
27412759	875	881	smears	T059	C1272593
27412759	889	897	multiple	T081	C0439064
27412759	898	904	single	T081	C0205171
27412759	905	918	tissue pieces	T024	C0040300
27412759	933	942	detection	T033	C0442726
27412759	943	950	methods	T170	C0025663
27412759	965	976	homogeneity	T080	C1881065
27412759	980	989	infection	T046	C3714514
27412759	993	998	liver	T023	C0023884
27412759	1003	1009	spleen	T023	C0037993
27412759	1018	1028	robustness	T080	C2986815
27412759	1046	1065	whole organ burdens	T081	C0005884
27412759	1073	1078	small	T081	C0700321
27412759	1079	1085	single	T081	C0205171
27412759	1086	1098	tissue piece	T024	C0040300
27412759	1100	1110	Comparison	T052	C1707455
27412759	1114	1117	pre	T079	C3539075
27412759	1124	1138	post-treatment	T079	C2709088
27412759	1139	1146	burdens	T078	C2828008
27412759	1150	1158	infected	T033	C0439663
27412759	1159	1167	hamsters	T015	C0018561
27412759	1184	1193	detection	T033	C0442726
27412759	1194	1201	methods	T170	C0025663
27412759	1215	1223	revealed	T080	C0443289
27412759	1235	1243	parasite	T204	C0030498
27412759	1244	1253	reduction	T080	C0392756
27412759	1261	1267	spleen	T023	C0037993
27412759	1268	1276	compared	T052	C1707455
27412759	1284	1289	liver	T023	C0023884
27412759	1305	1310	organ	T023	C0178784
27412759	1313	1322	dependent	T080	C0851827
27412759	1323	1332	clearance	T080	C0449297
27412759	1333	1341	efficacy	T080	C1280519
27412759	1346	1357	miltefosine	T109,T121	C0068006
27412759	1362	1372	conclusion	T078	C1707478
27412759	1379	1384	study	T062	C2603343
27412759	1392	1399	hamster	T015	C0018561
27412759	1413	1417	high	T080	C0205250
27412759	1418	1429	homogeneity	T080	C1881065
27412759	1433	1442	infection	T046	C3714514
27412759	1446	1451	liver	T023	C0023884
27412759	1456	1462	spleen	T023	C0037993
27412759	1488	1497	molecular	T080	C1521991
27412759	1498	1507	detection	T061	C1511790
27412759	1508	1515	methods	T170	C0025663
27412759	1520	1530	assessment	T058	C0220825
27412759	1534	1537	low	T080	C0205251
27412759	1539	1553	post-treatment	T079	C2709088
27412759	1555	1561	tissue	T024	C0040300
27412759	1562	1569	burdens	T078	C2828008